Filing Flows › Caribou Biosciences (CRBU) › Q2 2025
Caribou Biosciences (CRBU) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
Caribou Biosciences (CRBU) reported revenue of $2.7M for the second quarter 2025 (Q2 2025), -23% from a year earlier and +13% from the quarter before.
Caribou Biosciences, Q2 2025: revenue $2.7M (-23% year over year), net loss $54.1M, operating cash flow −$28.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.7M | +13% | -23% |
| Operating profit | −$47.6M | — | — |
| Net earnings | −$54.1M | — | — |
| Operating cash flow | −$28.3M | — | — |
What changed
Revenue was $2.7M in Q2 2025, down 23% year over year and up 13% from the previous quarter.
Operating costs exceeded revenue by $47.6M, an operating margin of -1784.0%. Total costs grew 7% against a revenue fall of 23%. The quarter ended with a net loss of $54.1M, wider than the previous quarter's $40.0M loss.
Operating cash flow was −$28.3M. Non-cash charges added back $1.2M of depreciation and amortization and $3.1M of share-based compensation. Working capital and other items added $21.5M. Capital expenditures of $418K exceeded it, leaving free cash flow of −$28.7M.
Questions
What was Caribou Biosciences' revenue in the second quarter 2025?
Caribou Biosciences (CRBU) reported revenue of $2.7M for the second quarter 2025 (Q2 2025), -23% from a year earlier and +13% from the quarter before.